The effect of COVID-19 vaccination on anticoagulation stability in adolescents and young adults using vitamin K antagonists

• Published in: Thrombosis research 2023-08, Vol.228, p.121-127
• Main Authors: Visser, Chantal, Yousefi, Arjen, Nierman, Melchior C., Huisman, Menno V., Gulpen, Anouk J.W., van Ommen, C. Heleen, Kruip, Marieke J.H.A.
• Format: Article
• Language: English
• Subjects: Acenocoumarol; Adolescent; Adult; Aged; Anticoagulants - therapeutic use; COVID-19 - prevention & control; COVID-19 vaccines; COVID-19 Vaccines - adverse effects; Cross-Over Studies; Female; Full Length; Humans; International Normalized Ratio - methods; Male; Phenprocoumon; Vitamin K; Young Adult
• ISSN: 0049-3848; 1879-2472
• DOI: 10.1016/j.thromres.2023.06.005

The European Medicine Agency has authorized COVID-19 vaccination in adolescents and young adults (AYAs) from 12 years onwards. In elderly vitamin K antagonist (VKA) users, COVID-19 vaccination has been associated with an increased risk of supra- and subtherapeutic INRs. Whether this association is also observed in AYAs using VKA is unknown. Our aim was to describe the stability of anticoagulation after COVID-19 vaccination in AYA VKA users. A case-crossover study was performed in a cohort of AYAs (12–30 years) using VKAs. The most recent INR results before vaccination, the reference period, were compared with the most recent INR after the first and, if applicable, second vaccination. Several sensitivity analyses were performed in which we restricted our analysis to stable patients and patients without interacting events. 101 AYAs were included, with a median age [IQR] of 25 [7] years, of whom 51.5 % were male and 68.3 % used acenocoumarol. We observed a decrease of 20.8 % in INRs within range after the first vaccination, due to an increase of 16.8 % in supratherapeutic INRs. These results were verified in our sensitivity analyses. No differences were observed after the second vaccination compared to before and after the first vaccination. Complications after vaccination occurred less often than before vaccination (9.0 vs 3.0 bleedings) and were non-severe. the stability of anticoagulation after COVID-19 vaccination was decreased in AYA VKA users. However, the decrease might not be clinically relevant as no increase of complications nor significant dose adjustments were observed. •COVID-19 vaccine affects Vitamin K antagonist (VKA) stability in elderly.•Case-crossover study was performed in adolescent and young adult (AYAs) users.•We observed an increase of 20.8 % INRs out of range after the first vaccination.•Anticoagulation stability also decreased in AYA VKA users after COVID-19 vaccination.•Decrease may not be clinically relevant as no increase of complications was seen.